| abstract |
The present disclosure concerns non-agglomerating bioconjugates of amylin, amylin-mimetic compounds, and combinations comprising the same, wherein said bioconjugate contains at least one acyl unit. Methodology of making and using are provided herein. In some embodiments, an instant non-agglomerating amylin bioconjugate can be used for treating a disease associated with a lack of natural production of amylin and/or deposition or accumulation of extracellular amyloid fibers, which contribute to the dysfunction or failure of systemic organs such as the pancreas or the brain. |